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Background: Health status assessment of senior adults is one of the most important aspects
of  a treatment decision making process. A group of elderly cancer patients is very heteroge-
neous according to the health status – some of them are ﬁt enough for aggressive treatment,
but others are frail and vulnerable. Treatment for the latter group has to be adapted and
carefully monitored.
Aim: To review and analyze relevant literature on the usage and optimization of Compre-
hensive Geriatric Assessment (CGA).
Materials and methods: Medline search of studies published between 2000 and 2011, con-
taining key words: Comprehensive Geriatric Assessment, aging, cancer in senior adults,
frailty.
Results: To recognize and address individual needs of senior adults, a special holistic
approach has been developed – comprehensive geriatric assessment (CGA). This tool is a
gold  standard in gerontooncology, recommended by International Society of Geriatric Oncol-
ogy.  CGA evaluates all important health domains, from physiology to social and economical
problems, using sets of different tests. Assessment has to be performed by a trained team,
including a physician, nurse and social worker. CGA has been clinically validated in many
studies, but it is still not clear whether CGA improves the outcome of treatment of the elderly
with cancer.
Conclusions: Complexity and multidimensionality of CGA pose a logistic challenge foreveryday clinical practice. Special senior programs, which could be developed inside com-
prehensive cancer center, focusing attention on seniors’ problems and needs seem to be a
way forward for geriatric oncology.
© 2012 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
vulnerable and frail, with numerous comorbidities and impair-1. BackgroundEuropean population is undergoing considerable demographic
transformation.1 Aging promotes various changes in phys-
iological and biological processes which may lead to the
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developing of cancer. Thus, oncologists have to face a new
challenge: treatment of cancer in a group of patients who  areCancer Center, Garbary St. 15, Poznan, Poland.
ment of functional status.
Treatment results in elderly patients with cancer are still
unsatisfactory. A striking minority of patients over 75 years are
blished by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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reated aggressively with radical intent, negatively impacting
urvival rate. It has been shown in breast and lung cancer2,3
s well as for most other cancer sites.4
What are the reasons for such a situation? An important
ole is played by the fact that age is considered to be the main
riterion of treatment decision, whereas senior population
s highly heterogeneous with regard to health status. Some
enior patients, despite relatively good condition before treat-
ent, experience the exhaustion of physiological reserves,
nder stress condition such as during treatment. They need
 careful assessment of changes in their health status and
daptation of treatment plan. The essence of appropriate eval-
ation of seniors’ health lies in its multidimensionality and
as to be performed in the most important domain of health.
 gold standard in geriatric evaluation of older patients, rec-
mmended by the International Society of Geriatric Oncology
SIOG), is the Comprehensive Geriatric Assessment (CGA).5 In
his thorough approach, a global health status of seniors is
ssessed in various domains by an interdisciplinary team. CGA
as been clinically validated in many  studies,6–8 although it is
till not clear whether the use of CGA inﬂuences overall sur-
ival of the elderly with cancer. Moreover, the complexity of
his approach requires the involvement of a team of special-
sts – minimally a physician, a nurse and a social worker. Full
GA is time consuming and logistically complex, which poses
 challenge to a multidisciplinary team in making a treatment
ecision for an individual senior.
.  Aim
he aim of this review is to analyze relevant literature on the
sage and optimization of CGA.
.  Materials  and  methods
edline search was performed of peer review studies
ublished between 2000 and 2011, containing keywords: Com-
rehensive Geriatric Assessment; aging; cancer in senior
dults; frailty. Reference lists from relevant studies were
canned to identify any additional studies.
.  Results
.1.  Comprehensive  geriatric  assessment  in  clinical
ractice
GA is a multidisciplinary process able to identify med-
cal, social, and functional abilities of older adults. This
pecial diagnostic procedure detects and explains patients’
imitations and problems missed by a standard physical exam-
nation which may affect results of oncological treatment.
oreover, needs of patients are recognized and addressed,
nd individual treatment and care plans are developed. CGA
sage in clinical practice is aimed at improvement in diagnos-
ic accuracy, predictability of outcomes, as well as monitoring
f the whole treatment process and follow-up.9
The concept of modern geriatric assessment was devel-
ped by Warren in the 1930s and expanded into aiotherapy 1 8 ( 2 0 1 3 ) 44–48 45
comprehensive set of instruments for geriatric evaluation.
Components of a full CGA include an evaluation of major
health domains: biological, functional, psychological and
social.10 Actual forms of CGA may vary depending on a cur-
rent geriatric program, resources and logistics, but main goals
remain the same. Modern experience with CGA in oncology
has its roots in the mid-1990s, when oncologists and geriatri-
cians made attempts to implement CGA in clinical practice.10
The complexity of CGA lies in its holistic approach11
and the interaction between health domains. This approach
requires the team to recognize the problems of a senior adult
and prepare a treatment and supportive care plan.10
The question is: how, for whom and when to use CGA and
if there is any equally valid alternative for this assessment?
4.2.  What  does  CGA  consist  of?
CGA assesses main health domains. In every tested domain,
many tools were developed and validated for evaluation of
each important aspect of senior’s condition. An assessment
of the physiological status is of extreme importance for plan-
ning of the individual, tailored treatment for older patients.
Aging is linked to the changes in liver, renal and bone mar-
row functions. Changes in the cytochrome p45 function may
potentially affect drug pharmacokinetics,12 as well as lower
the level of albumin. It has been shown that the albumin level
is an indicator of organism’s reserves and an independent
mortality risk factor.13 Similarly, a low level of hemoglobin cor-
relates with a higher mortality in older persons.14 Toxicity of
treatment also depends strongly on renal function. It is widely
known, that the creatinine level does not properly reﬂect the
renal function in the elderly, as normal values of this parame-
ter do not exclude renal impairment. The best way to properly
assess the renal function and its real reserve is to measure
creatinine clearance.
Low levels of hemoglobin and albumin are also predictors
of mortality and inﬂuencers of treatment outcome. SIOG task
force on CGA recommends integration of biochemical mark-
ers, such as albumin and hemoglobin levels and creatinine
clearance as vital elements, into an assessment of the tolera-
bility of planned treatment in the elderly.5
The inﬂuence of comorbidities on physiological status can-
not be omitted as many  of them affect the cardiac and renal
functions. The most often reported comorbidities in older
patients are related to cardiac and respiratory diseases. In
daily life, physicians can score the inﬂuence of comorbodi-
ties using Charlson Comorbidity Index (CCI).15 This test has
proved its clinical value, e.g. it has been demonstrated that
hypertension can lead to the intensiﬁcation of side effects
of taking trastuzumab and anthracyclines, in the form of
cardiomyopathy.16–18
Comorbidities lead to polypharmacy.  Many  medicines inter-
act with cytostatics or other agents used in oncological
treatment, bringing the risk of unexpected and potentially
serious adverse effects. A helpful tool in the evaluation of
potential drug toxicity is the Beers list, containing a list of
drugs which are potentially toxic for older patients19 as well
as the Medication Appropriateness Index (MAI) which may be
useful to measure appropriateness of prescription and opti-
mize pharmacological treatment.20
nd ra46  reports of practical oncology a
Functional status evaluation is a very important part of CGA.
The Activity Daily Life Scale (ADL)21 and Instrumental Activi-
ties of Daily Living Scale (IADL)22 are assessment tools which
are most often used in functional assessment and incorpo-
rated into CGA. It has been shown that the need of assistance
in ADL and IADL is a predictor of mortality in the population
of elderly cancer patients.23
Similarly, malnutrition can negatively affect treatment
results. ECOG analyzed a group of 3047 patients and demon-
strated that weight loss before the start of chemotherapy had
a negative impact on survival.24 Malnutrition is the prob-
lem in about half of elderly patients. Nutrition status has to
be taken into account before treatment and then assessed
on a regular basis during treatment. Nausea and mucositis,
loss of appetite and sense of taste result in food aversion
which may lead to malnutrition, and dehydration with subse-
quent electrolyte imbalance, hypoalbuminemia and anemia.
Instruments for assessment of nutrition status such as the
Malnutrition Screening Tool (MST),25 Malnutrition Universal
Screening Tool (MUST)26 or Nutrition Risk Screening (NRS)27
are easy to use in daily practice. The most popular test is
the Mini Nutritional Assessment (MNA)28 or its Short Form
(MNA-SF).29
Psychological and cognitive impairment are often underesti-
mated in clinical evaluation. Clinicians are not prepared to
assess properly the psychological status of elderly patients.
The problem is important in the light of the fact that up to 20%
of people over 65 years suffer from depression.30 Psychologi-
cal impairments like depression, delirium or dementia lead
to the loss of appetite, malnutrition and low treatment com-
pliance. Scales to evaluate mental status of older patients are
well known, e.g. a general scale: Mini Mental State Examina-
tion test (MMSE) and the more  specialized Hospital Anxiety
and Depression Scale (HADS)31 and Geriatric Depression Scale
(GDS), mostly used by geriatricians.32
Social worker is a very important member of a treatment
team as the social and economic status of senior adults is often
ignored by physicians. Older patients experience loneliness
and are in need of emotional support as well as ﬁnancial assis-
tance. To recognize and address their needs, special tests are
included in CGA. Good examples of such tools are: Medical
Outcomes Study Social Activity Limitations Measure (MOS)33
and Medical Outcomes Study Social – Support Survey: Emo-
tional/Information and Tangible Subscales. These tests can
also be easily used in daily practice, not only in the CGA frame-
work.
4.3.  A  concept  of  frailty
CGA assessment allows to divide patients into three groups:
ﬁt, intermediate or frail.39 There are few deﬁnitions of frailty
in the literature. Frailty was generally deﬁned by the Ameri-
can Medical Association as a condition present in a group of
patients with the most complex and challenging problems,
with higher probability of mortality and hospitalization.40Decrease of nutrition, mobility, strength, energy and physical
activity are ﬁve hallmarks of frailty according to Fried.41,42 Cur-
rently, also mood and cognition impairments are recognized
as additional features of frailty.43 Frailty can also be causeddiotherapy 1 8 ( 2 0 1 3 ) 44–48
by cancer itself – making patients weak due to cachexia or
dependent due to pathological fracture or pain
Recognizing frailty is one of the most important tasks
of geriatric assessment, because it allows to detect patients
with low physical reserves among relatively ﬁt seniors. Such
patients need initial adaptation of treatment plan, as they are
experiencing higher toxicity of treatment affecting results of
the treatment.
4.4.  Quality  of  life  (QoL)
Assessment of quality of life in elderly cancer patients is
another important aspect of senior’s condition. Quality of life
is deﬁned by WHO  as “an individual’s perception of their posi-
tion in life in the context of the culture and value systems in
which they live and in relation to their goals, expectations,
standards and concerns.”34 QoL can be affected not only by
aging itself, but also by cancer and treatment related toxicity.
Evaluation of QoL according to a WHO  deﬁnition is subjec-
tive, thus results of this self-reported test can be different from
physician’s examination and detect health problems not cap-
tured by other tests. A good example of QoL questionnaire is
the elderly module of EORTC, QLQ-30, designed and validated
by the European Organization for Research and Treatment of
Cancer (EORTC).35 This questionnaire is widely used in daily
practice and focused on different domains of life. Wedding
et al. reported that for elderly patients diagnosed with can-
cer, quality of life seems to be even more  important than gain
in survival after treatment.36 Moreover, impairments in CGA
tests are related to decreasing of QoL measured by a HRQoL
(Health Related Quality of Life) questionnaire.36 Many  studies
have shown that repeating QoL tests during the course of treat-
ment can be a valuable tool not only for tailoring treatment for
seniors37,38 but also as a predictor of survival.36
5. Discussion
A Complex Geriatric Assessment allows for identiﬁcation of
geriatric problems which are often missed in standard clin-
ical examination and for evaluation of beneﬁts and risks of
standard treatment in the elderly. It allows a MDT  for adapta-
tion of planned treatment. Caillet et colleagues demonstrated
that an initial treatment plan for patients at the mean age of
79.6 years was modiﬁed for 20.8% of patients after CGA. They
found ADL dependence and malnutrition independently asso-
ciated with adaptation to treatment of cancer in multivariate
analysis.44 Another study by Extermann showed that in early
breast cancer in senior adults CGA repeated every 3 months
discovered 6 health problems per patient which otherwise
would not be detected.45 Such difﬁculties like hearing and
vision impairment, incontinence or dental problems, seem-
ingly insigniﬁcant and easy to remove may affect results of
treatment and quality of life. Thus, repeated assessment of
elderly population should be of interest for every oncologist
and geriatrician. How and when to re-evaluate senior patients
still needs to be determined. Oncologists’ community is aware
that geriatric assessment must be incorporated widely into
everyday clinical practice. Despite this knowledge, full geri-
atric assessment of every patient older than 65 years remains
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 challenge for a busy oncological department. Due to the com-
lexity of CGA, there is a need of short and simple screening
ools, which would allow for identiﬁcation of frail and vul-
erable patients who need full CGA before treatment. Such a
wo-step approach is recommended by SIOG. Screening tools
onsisting of a combination of clinical tests in different health
omains are currently under clinical validation46 in order to
nd a most sensitive, speciﬁc and simple instrument.
To implement a holistic health care for senior adults with
ancer some of cancer centers have developed special pro-
rams for older patients. A good example is the Mofﬁt Cancer
enter and its Senior Adults Oncology Program (SAOP).47,48
he SAOPs team consists of physicians, nurse, dieteticians,
ocial workers and rehabilitation therapists. They are trained
n oncology and committed to treatment of comorbidities
inked to aging. The aim of the program is to make a com-
rehensive geriatric assessment by multidisciplinary team,
o identify and treat seniors’ problems related to cancer
reatment, and quality of daily life. Dedicated tools for the
alculation of treatment’s toxicity, i.e. the Chemotherapy Risk
ge Scale Age for High Risk Patients (CRASH)49 are used by
he SOAP for treatment decision making and adaptation. The
evelopment of such programs inside cancer centers seems
o be a right way to optimize organization of health care for
lder patients and to treat cancer in a proper way, with time
nd attention for the patient and her/his needs.
.  Conclusions
ssessment of health status of senior adults with cancer is one
f the most important tasks in a treatment decision-making
rocess. CGA is recommended as a clinically validated gold
tandard in health status assessment. Despite its value, CGA
eems to be a time- and manpower consuming procedure,
hich encourages oncologists and geriatricians to develop
horter screening tools to replace a full CGA.
The best way to improve treatment and care for elderly with
ancer is implementation of institutional programs of holistic
are for this group of patients.
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